Immunotech Laboratories (IMMB) Stock Price
Immunotech Laboratories Price
The stock trades about 100% above its 52-week low.
Immunotech Laboratories stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Immunotech Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immunotech Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immunotech Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Immunotech Laboratories Price |
|---|---|
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
| 7/16/2026 | 0.00 USD |
| 7/15/2026 | 0.00 USD |
| 7/14/2026 | 0.00 USD |
| 7/13/2026 | 0.00 USD |
| 7/10/2026 | 0.00 USD |
| 7/9/2026 | 0.00 USD |
| 7/8/2026 | 0.00 USD |
| 7/7/2026 | 0.00 USD |
| 7/6/2026 | 0.00 USD |
| 7/3/2026 | 0.00 USD |
| 7/2/2026 | 0.00 USD |
| 7/1/2026 | 0.00 USD |
| 6/30/2026 | 0.00 USD |
| 6/29/2026 | 0.00 USD |
| 6/26/2026 | 0.00 USD |
| 6/25/2026 | 0.00 USD |
| 6/24/2026 | 0.00 USD |
| 6/23/2026 | 0.00 USD |
| 6/22/2026 | 0.00 USD |
| 6/19/2026 | 0.00 USD |
| 6/18/2026 | 0.00 USD |
| 6/17/2026 | 0.00 USD |
| 6/16/2026 | 0.00 USD |
| 6/15/2026 | 0.00 USD |
| 6/12/2026 | 0.00 USD |
| 6/11/2026 | 0.00 USD |
| 6/10/2026 | 0.00 USD |
| 6/9/2026 | 0.00 USD |
| 6/8/2026 | 0.00 USD |
| 6/5/2026 | 0.00 USD |
| 6/4/2026 | 0.00 USD |
| 6/3/2026 | 0.00 USD |
| 6/2/2026 | 0.00 USD |
| 6/1/2026 | 0.00 USD |
| 5/29/2026 | 0.00 USD |
| 5/28/2026 | 0.00 USD |
| 5/27/2026 | 0.00 USD |
| 5/26/2026 | 0.00 USD |
| 5/22/2026 | 0.00 USD |
| 5/21/2026 | 0.00 USD |
| 5/20/2026 | 0.00 USD |
| 5/19/2026 | 0.00 USD |
| 5/18/2026 | 0.00 USD |
| 5/15/2026 | 0.00 USD |
| 5/14/2026 | 0.00 USD |
| 5/13/2026 | 0.00 USD |
| 5/12/2026 | 0.00 USD |
| 5/11/2026 | 0.00 USD |
| 5/8/2026 | 0.00 USD |
| 5/7/2026 | 0.00 USD |
| 5/6/2026 | 0.00 USD |
| 5/5/2026 | 0.00 USD |
| 5/4/2026 | 0.00 USD |
| 5/1/2026 | 0.00 USD |
| 4/30/2026 | 0.00 USD |
| 4/29/2026 | 0.00 USD |
| 4/28/2026 | 0.00 USD |
| 4/27/2026 | 0.00 USD |
| 4/20/2026 | 0.00 USD |
| 3/25/2026 | 0.00 USD |
| 2/18/2026 | 0.00 USD |
| 1/27/2026 | 0.00 USD |
| 1/22/2026 | 0.00 USD |
| 12/19/2025 | 0.00 USD |
| 12/9/2025 | 0.00 USD |
| 12/5/2025 | 0.00 USD |
| 11/24/2025 | 0.00 USD |
| 11/18/2025 | 0.00 USD |
| 11/13/2025 | 0.00 USD |
| 11/11/2025 | 0.00 USD |
| 10/2/2025 | 0.00 USD |
| 9/30/2025 | 0.00 USD |
| 8/28/2025 | 0.00 USD |
Immunotech Laboratories Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunotech Laboratories Income Statement, Balance Sheet, Cash Flow Statement
| EBITM USD |
|---|
| NET INCOMEM USD |
| SHARESk |
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2009 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | -2.00 | – |
| – | – | -1.00 | – | – | -33.00 | – |
| 1.40 | 1.80 | 1.90 | 2.20 | 2.60 | 41.90 | 41.90 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Immunotech Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immunotech Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immunotech Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Immunotech Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immunotech Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Immunotech Laboratories stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunotech Laboratories Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunotech Laboratories business model & stock analysis
Immunotech Laboratories SWOT Analysis
Strengths
Immunotech Laboratories Inc. excels in its advanced research and development capabilities. The company's scientific expertise enables it to innovate and stay at the forefront of the biotechnology industry, allowing for the development of groundbreaking solutions.
Immunotech Laboratories Inc. possesses a robust intellectual property portfolio, including patents, trademarks, and proprietary technologies. This portfolio grants the company a competitive advantage, protecting its innovations and offering opportunities for lucrative licensing agreements.
With a diversified product portfolio, Immunotech Laboratories Inc. mitigates risk and maximizes market opportunities. The company offers a range of biotech products addressing various diseases and conditions, ensuring multiple revenue streams and reducing dependency on a single product line.
Weaknesses
One of the weaknesses of Immunotech Laboratories Inc. is its reliance on external funding sources for research and development initiatives. This vulnerability exposes the company to potential financial constraints and fluctuations in funding availability.
Despite its strengths, Immunotech Laboratories Inc. has a relatively small market presence compared to established industry giants. This limited market reach may hinder the company's ability to compete effectively and gain significant market share.
Opportunities
The growing demand for biotech solutions presents a significant opportunity for Immunotech Laboratories Inc. to expand its customer base and boost revenue. The increasing prevalence of diseases and the need for effective treatments positions the company for potential growth and market penetration.
Immunotech Laboratories Inc. can leverage collaboration and partnerships with other biotechnology firms, academic institutions, and healthcare organizations. Such alliances provide access to additional resources, expertise, and market networks, enabling the company to accelerate research, development, and commercialization efforts.
Threats
Immunotech Laboratories Inc. faces fierce competition within the highly competitive biotechnology industry. Rival companies with larger market shares and established customer bases may pose a challenge to the company's growth and market positioning.
The biotech industry is subject to stringent regulations and compliance requirements. Immunotech Laboratories Inc. must navigate and comply with various regulatory frameworks, which can be complex, time-consuming, and costly. Failure to meet these obligations may result in penalties or restrictions on product development and commercialization activities.
Immunotech Laboratories Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Immunotech Laboratories historical P/E ratio, EBIT multiple, and P/S ratio
Immunotech Laboratories annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Immunotech Laboratories shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunotech Laboratories stock splits
Immunotech Laboratories Executives and Management Board
2 members · avg. age 44 · 0 % women
Management
Mr. Harry Zhabilov (44)
Vice Chairman of the Board, Chief Science Officer · since 2007
Board of Directors
Dr. Roscoe Moore
Director
Frequently asked questions about Immunotech Laboratories
The business model of Immunotech Laboratories Inc. focuses on research, development, and commercialization of biopharmaceutical products in the field of HIV/AIDS. The company is dedicated to creating innovative treatments and therapies to improve the lives of individuals living with this disease. Immunotech Labs utilizes cutting-edge technology and collaborations with experts in the industry to develop novel therapeutics for HIV/AIDS patients. With a strong emphasis on research and development, Immunotech Labs aims to bring effective and accessible treatment options to market, ultimately contributing to the fight against HIV/AIDS.
Immunotech Laboratories Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Immunotech Laboratories Inc in the market include companies such as Johnson & Johnson, GlaxoSmithKline, Pfizer, and Merck & Co.
Immunotech Laboratories Inc is a biopharmaceutical company specializing in the development and commercialization of immunotherapy products for the treatment of HIV/AIDS and cancer. Established in 2007, the company has since focused on researching and advancing its flagship product, Immunotherapy V5, which aims to boost the body's immune system to fight against these diseases. With a focus on innovative and cutting-edge therapies, Immunotech Laboratories Inc has gained recognition in the healthcare industry. By continuously investing in scientific advancements and clinical trials, the company strives to provide breakthrough treatments that can improve the quality of life for patients worldwide.
Immunotech Laboratories Inc has achieved several significant milestones. The company successfully developed the unique technology, LDN (Low Dose Naltrexone), which has shown promising results in treating HIV/AIDS. Furthermore, Immunotech Laboratories Inc has conducted clinical trials for their LDN therapy, demonstrating its potential in reducing viral load and increasing CD4 count in patients. The company has also received FDA approval for IND application, allowing them to continue their research and development efforts. Immunotech Laboratories Inc's advancements in LDN treatment have positioned them as a leading player in the field of immunotherapy for HIV/AIDS.
Immunotech Laboratories Inc is primarily present in the United States of America (USA).
Immunotech Laboratories Inc represents core values of innovation, dedication, and patient-centricity. With a commitment to developing advanced therapeutic solutions, Immunotech aims to improve patients' quality of life. The company's corporate philosophy revolves around providing cutting-edge medical technologies that address unmet medical needs, paving the way for breakthrough treatments. Immunotech Laboratories Inc strives to prioritize patient well-being, harnessing advanced scientific research to develop effective immunotherapies. By placing patients at the center of their endeavors, Immunotech exemplifies their dedication to solving critical health challenges and improving global healthcare outcomes.
Converted at the current exchange rate, the Immunotech Laboratories share trades at 0.00 EUR (0.00 USD).
Immunotech Laboratories Inc. is a company in the biotechnology industry that specializes in the development and marketing of immunotherapies for the treatment of chronic and severe diseases. The company's business model is based on innovative technologies and research findings that enable it to develop effective and safe products that improve the health and well-being of patients around the world.
The revenue cannot currently be calculated for Immunotech Laboratories.
The profit cannot currently be calculated for Immunotech Laboratories.
The P/E ratio cannot be calculated for Immunotech Laboratories at the moment.
The P/S cannot be calculated for Immunotech Laboratories currently.
The Eulerpool Quality Score for Immunotech Laboratories is 2/10.
The ISIN of Immunotech Laboratories is US45254F2039. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Immunotech Laboratories is A0RF8Y. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Immunotech Laboratories is IMMB. The ticker symbol is used to trade Immunotech Laboratories shares on the stock exchange.
Immunotech Laboratories paid dividends every year for the past 0 years.
Immunotech Laboratories is assigned to the 'Health' sector.
The dividends of Immunotech Laboratories are distributed in USD.
Immunotech Laboratories stock
Immunotech Laboratories Peer Group
Immunotech Laboratories Ticker
Immunotech Laboratories FIGI
All fundamentals and in-depth analysis of Immunotech Laboratories
Our stock analysis for Immunotech Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunotech Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.